KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Share-based Compensation (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Share-based Compensation readings, the most recent being $23.8 million for Q4 2025.

  • On a quarterly basis, Share-based Compensation rose 11.5% to $23.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $85.1 million, a 30.04% increase, with the full-year FY2025 number at $85.1 million, up 30.04% from a year prior.
  • Share-based Compensation hit $23.8 million in Q4 2025 for Biocryst Pharmaceuticals, up from $18.6 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $23.8 million in Q4 2025 to a low of $5.5 million in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $13.4 million (2024), compared with a mean of $14.3 million.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 353.5% in 2021 and later decreased 23.62% in 2022.
  • Biocryst Pharmaceuticals' Share-based Compensation stood at $8.5 million in 2021, then soared by 79.79% to $15.3 million in 2022, then grew by 7.89% to $16.5 million in 2023, then grew by 29.42% to $21.3 million in 2024, then rose by 11.5% to $23.8 million in 2025.
  • The last three reported values for Share-based Compensation were $23.8 million (Q4 2025), $18.6 million (Q3 2025), and $21.3 million (Q2 2025) per Business Quant data.